Co-Diagnostics, Inc. (CODX) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Co-Diagnostics, Inc. (CODX) closed at USD 0.76 on 2026-10-14, a change of -95.5 % over the past year, with a market capitalization of USD 4.99M.

Co-Diagnostics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Co-Diagnostics, Inc. key figures

Previous close

USD 0.76 (2026-10-14)

1-year change

-95.5 %

Market cap

USD 4.99M

Enterprise value

USD 2.62M

P/E ratio (trailing)

-0.04

P/E ratio (forward)

-0.86

EPS (trailing)

-17.63

EPS (forward)

-0.83

PEG ratio

n/a

Price to book

0.27

Revenue growth

2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.73

Employees

115

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Co-Diagnostics, Inc. and compare it with other stocks.